Praxis Precision Medicines (PRAX) Expected to Announce Earnings on Thursday

Praxis Precision Medicines (NASDAQ:PRAX) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Praxis Precision Medicines to post earnings of ($3.00) per share and revenue of $0.2560 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 19, 2026 at 8:00 AM ET.

Praxis Precision Medicines Stock Up 3.4%

PRAX stock opened at $328.04 on Wednesday. The stock has a market cap of $8.26 billion, a PE ratio of -25.43 and a beta of 2.84. The firm’s 50-day simple moving average is $296.63 and its 200 day simple moving average is $174.11. Praxis Precision Medicines has a fifty-two week low of $26.70 and a fifty-two week high of $335.75.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on PRAX shares. Wells Fargo & Company began coverage on Praxis Precision Medicines in a report on Monday, February 2nd. They set an “equal weight” rating and a $282.00 price target on the stock. Jefferies Financial Group restated a “buy” rating and issued a $450.00 target price (up from $300.00) on shares of Praxis Precision Medicines in a research report on Tuesday, December 9th. Oppenheimer reiterated an “outperform” rating and set a $750.00 price target (up previously from $250.00) on shares of Praxis Precision Medicines in a research report on Monday, December 15th. Citigroup reissued a “conviction-buy” rating on shares of Praxis Precision Medicines in a research note on Tuesday, December 30th. Finally, Guggenheim restated a “buy” rating and set a $800.00 price objective (up from $760.00) on shares of Praxis Precision Medicines in a research note on Tuesday, February 10th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $536.06.

Insider Transactions at Praxis Precision Medicines

In other news, insider Lauren Mastrocola sold 13,600 shares of Praxis Precision Medicines stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $192.08, for a total value of $2,612,288.00. Following the transaction, the insider owned 10,442 shares of the company’s stock, valued at $2,005,699.36. The trade was a 56.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Alex Nemiroff sold 25,130 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $193.09, for a total transaction of $4,852,351.70. Following the sale, the general counsel directly owned 20,832 shares of the company’s stock, valued at approximately $4,022,450.88. This represents a 54.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Praxis Precision Medicines

Institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Praxis Precision Medicines by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,708 shares of the company’s stock valued at $444,000 after purchasing an additional 573 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Praxis Precision Medicines by 367.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 87,081 shares of the company’s stock valued at $3,298,000 after buying an additional 68,466 shares in the last quarter. Creative Planning acquired a new position in Praxis Precision Medicines during the second quarter valued at $273,000. JPMorgan Chase & Co. lifted its stake in Praxis Precision Medicines by 21.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 13,938 shares of the company’s stock worth $586,000 after acquiring an additional 2,459 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in Praxis Precision Medicines by 15.7% during the 2nd quarter. Legal & General Group Plc now owns 16,670 shares of the company’s stock worth $701,000 after acquiring an additional 2,261 shares during the period. 67.84% of the stock is owned by institutional investors and hedge funds.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.